



Claims

- 1 A method of treating or preventing pulmonary hypertension in a patient which comprises treating the patient with an effective amount of a PDE5 inhibitor selected from the group:


- 5
- SUB
BI*
- 10
- a) sildenafil;
- b) (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;
- c) 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- d)



e)




15 f)



; and

17

g)

SUB
B1

or a pharmaceutically acceptable salt, solvate or polymorph; or a pharmaceutical composition thereof.

5

2

A method according to claim 1 wherein the PDE5 inhibitor is sildenafil.

3

A method according to claim 1 or 2 wherein the effective amount is less than 50 mg per day.

4

A method according to claim 1 or 2 wherein the effective amount is up to 20 mg per day.

5

A method according to claim 1 or 2 wherein the effective amount is up to 10 mg per day.

15

6

A method according to claim 1 or 2 wherein the effective amount is from 1 to 10 mg per day.

20

7

A method according to any preceding claim wherein the PDE5 inhibitor is administered orally.

8

A method according to claim 7 wherein the PDE5 inhibitor is sildenafil citrate.

9

A method according to any one of claims 1 to 6 wherein the PDE5 inhibitor is inhaled.


10

A method according to claim 9 wherein the PDE5 inhibitor is sildenafil mesylate.


18

11 The use of a PDE5 inhibitor selected from the group:

- a) sildenafil;
b) (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;
5 c) 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
d)




e)




10

f)



; and

g)



or a pharmaceutically acceptable salt, solvate or polymorph thereof; for the manufacture of a medicament for treating or preventing pulmonary hypertension.

- 5 12 The use according to claim 11 wherein the PDE5 inhibitor is sildenafil.
- 13 The use according to claim 11 or 12 wherein the effective amount is less than 50 mg per day.
- 10 14 The use according to claim 11 or 12 wherein the effective amount is up to 20 mg per day.
- 15 The use according to claim 11 or 12 wherein the effective amount is up to 10 mg per day.
- 15 16 The use according to claim 11 or 12 wherein the effective amount is from 1 to 10 mg per day.
- 17 The use according to any one of claims 11 to 16 wherein the PDE5 inhibitor is administered orally.
- 20 18 The use according to claim 17 wherein the PDE5 inhibitor is sildenafil citrate.
- 19 The use according to any one of claims 11 to 16 wherein the PDE5 inhibitor is inhaled.
- 25 20 The use according to claim 19 wherein the PDE5 inhibitor is sildenafil mesylate.

Ad
C2